Form 4: Ironwood Pharmaceuticals Director Mark Currie Receives Significant Equity Grant

Ironwood Pharmaceuticals, Inc. Director Mark Currie was granted 45,000 shares of Class A Common Stock as part of the company's non-employee director compensation policy.

Summary

• Mark G. Currie, a Director of Ironwood Pharmaceuticals, Inc. (IRWD), acquired 45,000 shares of Class A Common Stock on June 10, 2025.
• The shares were acquired at a price of $0, indicating a grant rather than a cash purchase.
• This grant was made pursuant to the company's Second Amended and Restated Non-employee Director Compensation Policy, which became effective on January 1, 2024.
• Following this transaction, Mr. Currie's direct beneficial ownership of Class A Common Stock increased to 613,419 shares.
• The restricted stock is scheduled to vest in full on the date immediately preceding the annual meeting of stockholders for the next calendar year.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as it indicates a routine and expected compensation event for a director, aligning their interests with shareholders. It does not present any negative surprises or significant new information.

Positives

• The grant of 45,000 shares to Director Mark Currie aligns his interests with those of shareholders, as his compensation is directly tied to the company's equity performance.
• The transaction reflects the ongoing implementation of the company's established non-employee director compensation policy, indicating stable and transparent corporate governance practices.

Negatives

• No direct negative financial implications for the company are immediately apparent from this routine compensation grant.

Risks

• No specific risks are detailed in this Form 4 filing, which primarily reports an insider transaction.

Future Outlook

The document indicates that the granted restricted stock will vest in full on the date immediately preceding the annual meeting of stockholders for the next calendar year, which is a forward-looking event related to compensation.

Industry Context

This Form 4 filing is a routine disclosure of an insider equity transaction, specifically a stock grant to a non-employee director. Such grants are common practice across industries, including pharmaceuticals, to align director incentives with shareholder interests and are part of standard corporate governance. It does not provide broader industry trends or competitive insights.

Comparison to Industry Standards

• The grant of restricted stock to a non-employee director at a $0 price is a standard form of equity compensation in publicly traded companies, including those in the pharmaceutical sector.
• While specific comparable companies or projects are not mentioned in the document, this practice is consistent with typical compensation structures for board members across major indices, aiming to foster long-term alignment between directors and shareholders.

Corporate Governance

Related Party Transactions

• The grant of 45,000 shares of Class A Common Stock to Mark G. Currie, a Director of Ironwood Pharmaceuticals, Inc., constitutes a related party transaction as it involves compensation to a member of the company's board. This is a standard and disclosed form of compensation.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders by tying a portion of his compensation to the company's stock performance, potentially encouraging long-term value creation.
• Employees: No direct impact on employees is indicated by this specific filing.
• Customers: No direct impact on customers is indicated.
• Suppliers: No direct impact on suppliers is indicated.
• Creditors: No direct impact on creditors is indicated.

Next Steps

• The restricted stock granted to Mark Currie is expected to vest in full on the date immediately preceding the annual meeting of stockholders for the next calendar year.

Key Dates

Keywords

Ironwood Pharmaceuticals, IRWD, SEC Form 4, Insider Transaction, Stock Grant, Director Compensation, Restricted Stock, Equity Compensation, Mark Currie